Lipocine (Lipocine) Total Current Assets : $25.32 Mil (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Lipocine Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Lipocine's total current assets for the quarter that ended in Mar. 2024 was $25.32 Mil.

Lipocine Total Current Assets Historical Data

The historical data trend for Lipocine's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipocine Total Current Assets Chart

Lipocine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

19.63

25.33

46.38

34.14

22.86

Lipocine Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															30.62	27.09	24.61	22.86	25.32

Lipocine Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Lipocine's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	22.036	+	0.052	+	0	+	0.773
	=	22.86

Lipocine's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	24.632	+	0.1	+	0	+	0.583
	=	25.32

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Lipocine (NAS:LPCN) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Lipocine's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	24.632	-	1.49	+	0.75 * 0	+	0.5 * 0
=	23.14

Lipocine Total Current Assets Related Terms

Thank you for viewing the detailed overview of Lipocine's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipocine (Lipocine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (NAS:LPCN) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108

Website

http://www.lipocine.com

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.

Executives

Mahesh V. Patel	director, officer: President and CEO	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Richard Dana Ono	director	18 SPRING ROAD, CONCORD MA 01742
Spyridon Papapetropoulos	director	C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
George Nomikos	officer: Chief Medical Officer	675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Krista Fogarty	officer: Principal Accounting Officer	675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Jill M. Jene	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
John W. Higuchi	director	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Morgan R Brown	officer: EVP and CFO	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Stephen A Hill	director	50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Jeffrey Arvin Fink	director	2265 MORNING STAR DRIVE, PARK CITY UT 84060
Gregory Brooks Bass	officer: EVP and Chief Commercial Offic	3228 BROOKSIDE DRIVE, FURLONG PA 18925
Jyrki Mattila	officer: Chief Business Officer	AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Srinivasan Venkateshwaran	officer: CTO and VP RandD	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Robert K. Merrell	officer: VP Finance	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Gerald T Simmons	officer: VP Corp Business Development	837 4TH AVE, SALT LAKE CITY UT 84103